June 7th, 2017 – Recent surveys show that over half of the British population are unaware that radiotherapy options exist for cancers, benign conditions or palliative care1. This means that thousands of patients could be missing out on the best possible treatment....
Dupuytren's contracture is incredibly common, with rates in England of 20% of the population over the age of 65 having the disease. Causing a debilitating curling of fingers and toes, the most common treatment is surgery, causing long term and painful recovery....
Xstrahl is looking forward to participating in ARR 2017: Improving Radiotherapy Response through Radiation Research conference, which will take place on 26 - 28 June at St Hilda's College, Oxford. The three day annual event is aimed to trigger discussion on the latest...
Purpose/Objective To establish a novel preclinical model for stereotactic radiosurgery with combined mouse-like phantom quality assurance in the setting of brain metastases. Material Methods C57B6 mice underwent intracranial injection of B16-F10 melanoma cells....
Xstrahl is pleased to be invited as a sponsor for BACR Tumour Microenvironment: Basic Science to Novel Therapies conference and BACR 3D Models Workshop taking place on 14 - 16 June in Nottingham, UK. The conference will cover a wide number of topics with sessions on...
ESTRO 36 in Vienna, Austria saw Xstrahl Medical and Life Sciences come together to display some of the advances in radiotherapy solutions over the last year between the 5th and 9th of May 2017.
The SARRP User Spring Symposium event gathers together thought leaders, scholars and operators of Xstrahl Small Animal Radiation Research (SARRP) systems from all over the world.
BACKGROUND: To develop a new molecular targeted treatment for brain (AVMs), identification of membrane proteins that are localised on the AVM endothelium is crucial. Current treatment methods are surgery and radiosurgery. However, complete occlusion post radiosurgery...
Modulation of the redox system in cancer cells has been considered a promising target for anti-cancer therapy. The novel MTH1 inhibitor TH588 proved tremendous potential in terms of cancer cell eradication, yet its specificity has been questioned by recent reports,...
Contact Us